Providence Health System Southern California
Providence Health System Southern California was paid $27.29M by Medicaid between Jan 2018 and Dec 2024, across 252 billing codes. Its largest line is 0450, Emergency room services — 15% of everything it billed.
TORRANCE, CA 90503
Next to other General Acute Care Hospital providers in California
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 207,505 | $4.20M | |
| 2019 | 167,857 | $4.33M | |
| 2020 | 124,125 | $2.83M | |
| 2021 | 135,569 | $3.71M | |
| 2022 | 122,071 | $4.41M | |
| 2023 | 138,687 | $4.73M | |
| 2024incomplete | 115,843 | $3.10M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 15% | 84,685 | 77,088 | $4.07M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.5% | 8,952 | 8,550 | $1.77M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 5.9% | 7,220 | 7,080 | $1.61M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 9,872 | 9,475 | $1.21M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.7% | 23,632 | 22,175 | $1.02M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 34,040 | 31,690 | $763K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.7% | 3,444 | 3,235 | $724K |
| 80053 | Comprehensive metabolic panel | 2.4% | 56,192 | 50,843 | $658K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.4% | 17,559 | 16,771 | $646K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.1% | 10,124 | 9,188 | $581K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.1% | 4,391 | 4,202 | $563K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.9% | 11,439 | 9,749 | $530K |
240 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 16,286 | $475K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.7% | 7,200 | $474K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 59,199 | $413K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 13,611 | $401K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.4% | 4,047 | $392K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 2,105 | $369K |
| 0762 | 1.3% | 2,920 | $366K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.3% | 6,879 | $354K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 4,870 | $354K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 6,602 | $338K |
| 83880 | 1.2% | 17,144 | $325K | |
| 71045 | Radiologic examination, chest; single view | 1.2% | 22,258 | $320K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 15,077 | $293K |
| 99199 | Unlisted special service, procedure or report | 1.1% | 7,814 | $293K |
| Z7502 | 1.0% | 7,921 | $278K | |
| 99284 | Emergency room visit (serious) | <1% | 3,600 | $269K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,666 | $262K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,030 | $241K |
| 84484 | <1% | 27,936 | $225K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 939 | $206K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,702 | $206K |
| 76830 | Ultrasound, transvaginal | <1% | 3,372 | $198K |
| 93971 | <1% | 2,040 | $161K | |
| 83690 | <1% | 25,872 | $155K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,686 | $151K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 981 | $142K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,396 | $138K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,550 | $135K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,866 | $133K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 16,892 | $126K |
| 93970 | <1% | 873 | $125K | |
| 0260 | <1% | 805 | $123K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 593 | $117K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,280 | $116K |
| Z9725 | <1% | 2,635 | $113K | |
| 76801 | <1% | 2,418 | $112K | |
| 99283 | Emergency room visit (moderate) | <1% | 2,018 | $104K |
| 76642 | <1% | 1,962 | $103K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,135 | $96K |
| 81001 | <1% | 31,017 | $96K | |
| 0761 | <1% | 3,402 | $95K | |
| 85730 | <1% | 19,037 | $95K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,965 | $95K |
| 87040 | <1% | 8,683 | $93K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,255 | $93K |
| 82550 | <1% | 18,200 | $92K | |
| 84703 | <1% | 11,996 | $90K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,762 | $90K |
| 77066 | Tomosynthesis, mammo | <1% | 734 | $83K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,132 | $80K |
| 85610 | <1% | 20,876 | $75K | |
| 97139 | <1% | 3,515 | $74K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 576 | $74K |
| 70496 | <1% | 306 | $73K | |
| 70486 | <1% | 475 | $70K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,476 | $67K |
| 0160 | <1% | 883 | $66K | |
| J1815 | Injection, insulin, per 5 units | <1% | 761 | $64K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,082 | $60K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,655 | $60K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 140 | $59K |
| 84145 | <1% | 4,237 | $58K | |
| 83605 | <1% | 4,965 | $57K | |
| 77065 | Tomosynthesis, mammo | <1% | 685 | $55K |
| 0250 | <1% | 23,591 | $54K | |
| J3490 | Unclassified drugs | <1% | 14,914 | $54K |
| 82553 | <1% | 5,321 | $50K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,619 | $48K |
| 84702 | <1% | 3,925 | $48K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,381 | $47K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,979 | $46K |
| 70498 | <1% | 192 | $46K | |
| 72100 | <1% | 1,590 | $45K | |
| 73630 | <1% | 2,069 | $45K | |
| 73030 | <1% | 1,895 | $44K | |
| 96376 | <1% | 3,418 | $43K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 206 | $41K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,645 | $38K |
| 73610 | <1% | 1,814 | $38K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,460 | $37K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,594 | $37K |
| 0301 | <1% | 920 | $36K | |
| 0300 | <1% | 531 | $36K | |
| 90715 | <1% | 1,096 | $33K | |
| 93017 | <1% | 771 | $32K | |
| 73562 | <1% | 1,641 | $32K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,747 | $30K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,098 | $27K |
| 73130 | <1% | 1,193 | $27K | |
| 80179 | <1% | 1,931 | $27K | |
| 93975 | <1% | 155 | $27K | |
| 80143 | <1% | 1,882 | $26K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,796 | $26K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,750 | $24K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,815 | $24K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,996 | $23K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 940 | $23K |
| 81003 | <1% | 10,306 | $22K | |
| 87186 | <1% | 2,446 | $22K | |
| 84481 | <1% | 1,771 | $22K | |
| 96367 | <1% | 734 | $20K | |
| 87081 | <1% | 3,699 | $20K | |
| 83735 | <1% | 3,712 | $19K | |
| 81025 | <1% | 4,133 | $18K | |
| 73110 | <1% | 648 | $17K | |
| 0940 | <1% | 340 | $17K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,498 | $17K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,935 | $17K |
| 82330 | <1% | 1,512 | $17K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,286 | $16K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 115 | $15K |
| 86850 | <1% | 2,750 | $15K | |
| 73502 | <1% | 492 | $15K | |
| 99221 | <1% | 588 | $15K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 898 | $15K |
| 86901 | <1% | 4,843 | $15K | |
| 87077 | <1% | 2,430 | $14K | |
| 87807 | <1% | 1,729 | $14K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,376 | $14K |
| 84439 | <1% | 1,912 | $14K | |
| 0710 | <1% | 560 | $14K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,708 | $13K |
| 86900 | <1% | 4,833 | $13K | |
| 86140 | <1% | 2,077 | $13K | |
| 74018 | <1% | 712 | $12K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 436 | $12K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,547 | $12K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 80 | $12K |
| 0258 | <1% | 319 | $12K | |
| 85379 | <1% | 1,512 | $11K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 1,214 | $10K |
| 72131 | <1% | 102 | $10K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 49 | $9K |
| 0270 | <1% | 6,461 | $9K | |
| 97750 | <1% | 200 | $9K | |
| 72040 | <1% | 279 | $9K | |
| 0214 | <1% | 13 | $8K | |
| 73564 | <1% | 303 | $7K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,180 | $7K |
| 97161 | <1% | 123 | $7K | |
| 0636 | <1% | 2,002 | $7K | |
| G0378 | Hospital observation service, per hour | <1% | 93 | $7K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 508 | $7K |
| 0306 | <1% | 283 | $7K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 528 | $6K |
| 87070 | <1% | 758 | $6K | |
| 0305 | <1% | 341 | $6K | |
| Z7610 | <1% | 966 | $6K | |
| 76641 | <1% | 61 | $6K | |
| 87205 | <1% | 1,473 | $6K | |
| V5008 | Hearing screening | <1% | 289 | $6K |
| J2704 | Injection, propofol, 10 mg | <1% | 110 | $6K |
| 81002 | <1% | 2,705 | $6K | |
| 80061 | Lipid panel | <1% | 787 | $5K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,258 | $5K |
| 70491 | <1% | 37 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 813 | $5K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 314 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,063 | $5K |
| 80047 | <1% | 797 | $5K | |
| 85027 | <1% | 968 | $4K | |
| 73140 | <1% | 263 | $4K | |
| 84100 | <1% | 1,198 | $4K | |
| 73080 | <1% | 145 | $4K | |
| 97163 | <1% | 27 | $4K | |
| 73700 | <1% | 12 | $3K | |
| 76870 | <1% | 93 | $3K | |
| 71020 | <1% | 137 | $3K | |
| 76770 | <1% | 52 | $3K | |
| 85652 | <1% | 787 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 53 | $3K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 76 | $2K |
| 0324 | <1% | 314 | $2K | |
| 92585 | <1% | 55 | $2K | |
| 97162 | <1% | 40 | $2K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 582 | $2K |
| 80076 | <1% | 327 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 283 | $2K |
| 87210 | <1% | 611 | $2K | |
| 71101 | <1% | 68 | $2K | |
| 87420 | <1% | 524 | $2K | |
| 85014 | <1% | 1,231 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 84 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 376 | $2K |
| 82010 | <1% | 307 | $2K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 82 | $2K |
| 87088 | <1% | 447 | $2K | |
| 71250 | <1% | 12 | $2K | |
| 0370 | <1% | 30 | $2K | |
| 73590 | <1% | 104 | $1K | |
| 92558 | <1% | 53 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 64 | $1K |
| 83930 | <1% | 186 | $1K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 6,072 | $1K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 17 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 61 | $1K |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 83 | $993.06 |
| 71010 | <1% | 73 | $960.40 | |
| 86308 | <1% | 136 | $945.84 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 52 | $865.05 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 144 | $846.76 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 291 | $844.31 |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 27 | $816.22 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 44 | $756.23 |
| 82077 | <1% | 64 | $733.60 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 24 | $730.58 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 33 | $722.33 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 63 | $570.03 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 65 | $527.17 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 65 | $509.26 |
| 97802 | <1% | 36 | $507.93 | |
| 84132 | <1% | 106 | $452.55 | |
| 73560 | <1% | 31 | $398.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 633 | $387.92 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 56 | $320.34 |
| 84550 | <1% | 100 | $260.76 | |
| 29515 | <1% | 31 | $227.97 | |
| A4649 | Surgical supply; miscellaneous | <1% | 1,426 | $224.48 |
| J1245 | Injection, dipyridamole, per 10 mg | <1% | 25 | $180.34 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 76 | $150.52 |
| J0706 | Injection, caffeine citrate, 5 mg | <1% | 13 | $140.92 |
| 87045 | <1% | 24 | $139.16 | |
| 0760 | <1% | 26 | $136.40 | |
| 29125 | <1% | 28 | $134.79 | |
| 0637 | <1% | 449 | $112.84 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 15 | $111.97 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 461 | $101.41 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 17 | $82.79 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 55 | $81.25 |
| 82247 | <1% | 14 | $33.29 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 17 | $20.42 |
| A9270 | Non-covered item or service | <1% | 154 | $16.61 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 74 | $14.01 |
| 0302 | <1% | 141 | $1.91 | |
| 99070 | <1% | 40 | $1.83 | |
| 0410 | 0% | 14 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 111 | $0.00 |
| 0307 | 0% | 44 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 29 | $0.00 |
| 0730 | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.